The VenaCure 1470 endovenous laser vein treatment (EVLT) system by AngioDynamics (Cambridge, England) features a 1470 nm laser that delivers its energy through the company's NeverTouch gold-tip laser fiber, which boosts tip visibility under ultrasound and eliminates chances of inadvertent fiber tip contact with the vein wall. Additional features include a choice of procedure kits, procedure accessories, a tumescent delivery system, and practice and market development resources.
-----
PRESS RELEASE
AngioDynamics Launches VenaCure(R) 1470nm Laser for Treatment of Varicose Veins
May 31, 2011 (Business Wire) — AngioDynamics (NASDAQ: ANGO) has expanded its VenaCure EVLT® System product offering with the global launch of the new VenaCure® 1470nm laser to treat varicose veins with greater energy efficiency.
“Our VenaCure 1470 endovenous laser has shown to be highly efficient in the treatment of varicose veins, as it utilizes a lower power output compared with other lasers to achieve effective vein closure,” said Tom Kupec, Vice President of Marketing for AngioDynamics. “The new laser is complemented by the benefits of our NeverTouch® gold-tip fiber, designed to result in improved procedure parameters for patients and physicians. As the market leader in endovenous laser vein ablation, this combined therapy is another example of our commitment to providing meaningful innovation benefitting patients and physicians worldwide.”
The VenaCure 1470nm laser’s light energy is precisely delivered through the NeverTouch gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than is the case with other wavelengths. The NeverTouch fiber’s jacketed tip has been engineered to maximize clinical efficacy and minimize post-operative pain and bruising. It has a lower power density and is designed to virtually eliminate the risk of direct contact between the laser fiber and vein wall.
“Our research group performed a carefully controlled clinical trial using the new VenaCure 1470 laser coupled with the NeverTouch fiber from AngioDynamics,” said Jose I. Almeida, MD, FACS, Managing Partner, Vascular Device Partners, LLC. “We found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period. By allowing for the more efficient transfer of energy to the vein, this new long wavelength laser translated into improved clinical outcomes as compared to short wavelength lasers we have studied.”
The VenaCure 1470nm lasers are manufactured in AngioDynamics’ Cambridge, U.K., facility, which has been established as a center of excellence and reliability. It has received the CE mark, and a 510k approval.
About the VenaCure EVLT System
AngioDynamics’ VenaCure EVLT® endovenous laser vein treatment offers patients a proven, minimally-invasive choice for treating the source of their varicose veins and provides them with immediate recovery and a return to normal daily routines. The VenaCure EVLT system includes lasers available in both 1470 and 810 wavelengths, a choice of procedure kits, procedure accessories, a tumescent delivery system, practice and market development resources, and more. The NeverTouch® gold-tip laser fiber, an integral part of AngioDynamics’ advanced varicose vein treatment, establishes a new standard for patient comfort, visibility and ease of use. The proprietary technology maximizes tip visibility under ultrasound and eliminates chances of inadvertent fiber tip contact with the vein wall, further improving safety and patient comfort. For more information on the VenaCure EVLT system, visit www.VenaCure-EVLT.com.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.